Abstract            Volume:5  Issue-7  Year-2017         Original Research Articles

Online ISSN : 2347 - 3215 Issues : 12 per year Publisher : Excellent Publishers Email : editorijcret@gmail.com

Acute coronary syndrome (ACS) refers to any group of clinical symptoms compatible with acute myocardial ischemia and includes unstable angina (UA), non ST-segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI). Ivabradine is a new bradycardiac agent acting on the If current channels of sinoatrial nodal cells to decrease the rate of diastolic depolarization and thus the heart rate. The primary and principal cause of acute coronary syndrome in more than 90% of the patients is the rupture of an atheromatus plaque, endothelial dysfunction and inflammation and formation of fatty streaks are the core distributors to atherosclerotic plaque formation. High Sensitivity C-reactive protein is a sensitive marker of inflammation. Increased levels of Hs-CRP are associated with endothelial dysfunction, vascular inflammation and in increase cardiovascular risk. The study (n=80) aims to evaluate the effect of Ivabradine on high sensitivity C-reactive protein levels and its effect on ACS therapy. The objective of the study to know the effect of ivabrdine of hs-CRP level and the assessment of cardiac risk. In the study of 80 patients, the patients was categorized into two groups, there is significant reduction of hs-CRP levels, but more significant in the group who is taking Ivabradine. Since P value is less than 0.001, in both groups the level of hs-CRP is significantly reduced. Since P>0.05 at admission there is no significant difference in the mean value of hs-CRP in both the groups. But after discharge the mean values is significantly different (P<0.05) and is concluded that the difference is more in GROUP 1 who is taking ivabradine.

Download this article as